Neurosense Therapeutics is trading 7.09% up at $0.45 after its August 31 announcement of an accelerated, capital-efficient PrimeC development strategy for ALS.
- The plan proposes a streamlined Phase 3 pathway and direct comparison with edaravone.
- It includes potential additional patent protection and targets a December 2026 Canadian submission.
- Biotech-sector strength, with XBI up 2.75%, is providing additional support; no September 2 company-specific announcement was identified.